We have collected information about Targeted Delivery Of Chemotherapeutics Tumor-Activated Prodrug Therapy for you. Follow the links to find out details on Targeted Delivery Of Chemotherapeutics Tumor-Activated Prodrug Therapy.
https://www.sciencedirect.com/science/article/pii/S0169409X97000951
This chapter will review the progress made in the area of targeted delivery of small chemotherapeutic drugs, discuss some of the shortcomings of the earlier approaches, and provide potential solutions that may help restore the promise of the targeted delivery approach for cancer therapy. 2. Tumor-activated prodrug (TAP) therapyAuthor: Ravi V.J Chari
https://www.sciencedirect.com/science/article/abs/pii/S0169409X97000951
Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy. Author ... The potential of targeted delivery of chemotherapeutic drugs for the treatment of cancer has not yet been realized owing to the difficulty of delivering therapeutic concentrations to the target site. ... more potent and specific antibody–drug conjugates, which ...Author: Ravi V.J Chari
https://www.ncbi.nlm.nih.gov/pubmed/10837619
Apr 06, 1998 · 1. Adv Drug Deliv Rev. 1998 Apr 6;31(1-2):89-104. Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy. Chari RV(1). Author information: (1)ImmunoGen, Inc., 148 Sidney Street, Cambridge, USA The potential of targeted delivery of chemotherapeutic drugs for the treatment of cancer has not yet been realized owing to the difficulty of delivering therapeutic …Author: Ravi V.J Chari
http://europepmc.org/abstract/MED/10837619
May 01, 1998 · Starting with a historical perspective, this review will end with a description of newer, more potent and specific antibody-drug conjugates, which behave like tumor-activated prodrugs that may yet fulfil the promise of the targeted delivery approach for the treatment of cancer.Author: Ravi V.J Chari
https://www.deepdyve.com/lp/elsevier/targeted-delivery-of-chemotherapeutics-tumor-activated-prodrug-therapy-XeHKuPrXV8
Read "Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy, Advanced Drug Delivery Reviews" on DeepDyve, the largest online rental service for scholarly research with thousands of academic publications available at your fingertips.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3105156/
Aug 28, 2011 · Synthetic derivatives of the microtubule-targeted agent maytansine, commonly known as d rug m aytansinoids or DMs, are emerging as potential cancer therapeutics. DM1 is an antibody-conjugatable maytansinoid that was developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery.Author: Manu Lopus
Searching for Targeted Delivery Of Chemotherapeutics Tumor-Activated Prodrug Therapy?
You can just click the links above. The data is collected for you.
